Sickle cell disease (SCD) is a chronic debilitating disorder affecting erythrocytes, which is especially prevalent throughout Sub-Saharan Africa and among individuals of African descent. Because malaria is thought to be a significant cause of morbidity and mortality in patients with SCD, malaria chemoprophylaxis is often recommended for these patients. In SCD, malaria chemoprophylaxis reduces malaria parasite count, anaemia and the need for blood transfusion, and improves clinical outcomes. However, the effectiveness of malaria chemoprophylaxis in the setting of SCD is based on a few studies conducted prior to the emergence of widespread antimalarial drug resistance. Consequently, it is uncertain what the optimal strategy for managing patients with SCD in malarious areas should be. Despite the widespread use of hydroxyurea in non-malarious regions, little is known about its effect in malaria-endemic areas or on malaria-related outcomes. On the one hand, hydroxyurea upregulates intercellular cell adhesion molecule 1 (ICAM-1), the cell surface receptor for adhesion of Plasmodium falciparum-infected erythrocytes, and theoretically, it could enhance parasite replication. On the other hand, hydroxyurea increases levels of foetal haemoglobin, which is protective against malaria. We explore what is currently known about the interactions between SCD and malaria and review the published literature on the efficacy of malaria chemoprophylaxis in SCD. We also consider alternative strategies, including hydroxyurea, in the reduction of malaria-associated morbidity and mortality in patients with SCD.
L'anémie falciforme (drépanocytose) est une maladie chronique débilitante qui affecte les érythrocytes et qui est particulièrement répandue en Afrique subsaharienne et chez les personnes d'ascendance africaine. Comme le paludisme est considéré comme une cause importante de morbidité et de mortalité chez les patients atteints de l'anémie falciforme, la chimioprophylaxie du paludisme est souvent recommandée chez ces patients. Dans l'anémie falciforme, la chimioprophylaxie du paludisme réduit l'intensité du parasite, l'anémie et la nécessité d'une transfusion sanguine et améliore les résultats cliniques. Cependant, l'efficacité de la chimioprophylaxie du paludisme dans le cadre de la l'anémie falciforme est basée sur quelques études menées avant l’émergence de la résistance maintenant répandue aux médicaments antipaludiques. Par conséquent, la stratégie optimale pour la prise en charge des drépanocytaires dans les zones paludéennes est incertaine. Malgré l'utilisation répandue de l'hydroxyurée dans les régions non paludéennes, on en sait peu sur ses effets dans les zones d'endémie du paludisme ou sur les résultats connexes du paludisme. D'une part, l'hydroxyurée régule la Molécule 1 d'Adhésion Intercellulaire (ICAM-1), récepteur de surface cellulaire pour l'adhérence des érythrocytes infectés par P. falciparum et, théoriquement, elle pourrait favoriser la réplication du parasite. D'autre part, l'hydroxyurée augmente les taux d'hémoglobine fœtale, ce qui est protecteur contre le paludisme. Nous explorons ce que l'on sait actuellement sur les interactions entre l'anémie falciforme et le paludisme, et passons en revue la littérature publiée sur l'efficacité de la chimioprophylaxie du paludisme dans l'anémie falciforme. Nous considérons également d'autres stratégies, y compris l'hydroxyurée, dans la réduction de la morbidité et de la mortalité associées au paludisme chez les patients atteints de l'anémie falciforme.
La Anemia de Células Falciformes (ACF) es un desorden crónico que afecta a los eritrocitos y que es especialmente prevalente en África subsahariana y entre individuos de descendencia Africana. Puesto que se cree que la malaria es una causa importante de morbilidad y mortalidad en pacientes con ACF, a menudo se recomienda quimioprofilaxis para la malaria a estos pacientes. En ACF, la quimioprofilaxis para malaria reduce el conteo de parásitos, la anemia y la necesidad de transfusiones de sangre y mejora los resultados clínicos. Sin embargo, la efectividad de la quimioprofilaxis de malaria en lugares con ACF se basa en pocos estudios realizados antes del surgimiento y diseminación de la resistencia a antimaláricos. En consecuencia, no está claro cual sería la estrategia óptima para manejar a los pacientes con ACF en áreas con malaria. A pesar del amplio uso de la hidroxiurea en regiones sin malaria, se conoce poco acerca de su efecto en áreas endémicas para malaria o sobre los resultados sobre la malaria. Por otro lado, la hidroxiurea regula la Molécula de Adhesión Intercelular 1 (ICAM-1), el receptor celular de superficie para la adhesión de eritrocitos infectados con P. falciparum y en teoría podría aumentar la replicación del parásito. Por otro lado, los niveles de hidroxiurea aumentan la hemoglobina fetal, que protege frente a la malaria. Hemos explorado lo que se conoce actualmente sobre las interacciones entre ACF y malaria, y revisado la literatura publicada sobre la eficacia de la quimioprofilaxis de malaria en ACF. También consideramos estrategias alternativas, incluyendo la hidroxiurea, para la reducción de la morbilidad y mortalidad asociadas con la malaria en pacientes con ACF.
Sickle cell disease (SCD), an autosomal recessive disease, is one of the most common genetic disorders in the world. In its heterozygous form (sickle cell trait), the haemoglobin S gene provides substantial protection against malaria. In its homozygous form, SCD leads to substantial morbidity and eventually death, typically within the first 2–3 decades of life. The gene responsible for haemoglobin S is common among peoples living in malaria-endemic regions of Africa (Serjeant 1989; Angastiniotis & Modell 1998; Modell & Darlison 2008; Piel et al. 2010) and appears to have emerged due to evolutionary pressure exerted principally by Plasmodium falciparum. Accordingly, the largest public health burden is in Sub-Saharan Africa where more than 200 000 children are born with the disorder each year (Angastiniotis & Modell 1998). Through a variety of pathophysiological mechanisms, malaria and SCD each potentiate the effects of the other, thus increasing morbidity and mortality and treatment cost.
Although recommended by the World Health Organization (WHO African Region 2010), there is limited evidence that malaria chemoprophylaxis is beneficial in persons with SCD. It is not known how commonly chemoprophylaxis is used or how antimalarial drug resistance affects its effectiveness. As a consequence, the optimal policy for long-term management of patients with SCD living in malarious areas remains to be identified.
In this article, we review the interactions between malaria and SCD and the evidence regarding strategies for mitigating the synergistic interactions between both conditions. We assess the effectiveness of chemoprophylaxis against malaria among patients with SCD, summarise the current limitations of our understanding and describe several promising novel approaches for co-managing these conditions.
We conducted a systematic review using MEDLINE, PubMed, Google Scholar and Cochrane review databases for all randomised controlled trials on malaria chemoprophylaxis in SCD in malaria-endemic zones ever published. The bibliographies of publications initially found were searched for other trials. We included publications of all levels of quality because so few trials were identified and we wanted to provide as much information as possible. We also searched the same databases for trials involving the use of non-conventional methods in potentiating the effects of malaria in SCD or the effects of SCD in malaria-endemic regions. A summary of the search method with search terms and their results is given in Table 1 and Figure 1.
|Sources||PubMed/MEDLINE, Web of Science, Cochrane Library of clinical trials|
|Search terms||Combinations of ‘sickle cell disease (SCD)’ and ‘malaria’, ‘malaria parasite’, ‘chemoprophylaxis’, ‘prevention’, ‘Plasmodium falciparum’, ‘antimalarial’|
|Limits||Studies conducted in humans, published in English, with access to full texts or abstracts|
|Eligibility||Clinical trials with one or more interventions involving malaria chemotherapeutic drugs or placebo|
|Outcomes||Malaria or SCD-related events|
|Inclusion criteria||All Studies regardless of methodological quality|
We categorised our findings based on levels of evidence. Where possible, we included the quality of evidence and strength of recommendation based the Infectious Diseases Society of America–US Public Health Service Grading System for ranking recommendations in clinical guidelines explained in Table 2.
|Strength of recommendation|
|A. Good evidence to support a recommendation for use; should always be offered|
|B. Moderate evidence to support a recommendation for use; should generally be offered|
|C. Poor evidence to support a recommendation; optional|
|D. Moderate evidence to support a recommendation against use; should generally not be offered|
|E. Good evidence to support a recommendation against use; should never be offered|
|Quality of evidence|
|I. Evidence from ≥1 properly randomised, controlled trial|
|II. Evidence from ≥1 well-designed clinical trial, without randomisation; from cohort or case controlled analytic studies (preferably from 11 centres); from multiple time-series; or from dramatic results from uncontrolled experiments|
|III. Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees|
Sickle cell disease
Globally, an estimated 275 000 babies are born annually with SCD. In Africa, the prevalence of the beta-globin gene mutation that determines the incidence of sickle cell disorders is about 15% (Angastiniotis & Modell 1998). However, the prevalence varies widely with the highest rates in equatorial Africa, approaching 20% of the population, while the prevalence is <1% in North Africa. Outside of Africa, SCD and sickle cell trait follow the worldwide diaspora of African populations (Serjeant 1989; Piel et al. 2010). For example, in the United States, approximately 90 000 individuals have SCD, mainly African Americans and approximately 2.5 million are carriers of the mutant gene (Centers for Disease Control & Prevention 2011).
Sickle cell disease was the first disease conclusively linked to abnormalities in protein structure and function (Pauling et al. 1949). Inherited in a strict Mendelian fashion, haemoglobin S, the abnormal haemoglobin responsible for SCD, arises from a point mutation in the β globin gene, in which thymine is replaced by adenine in the 17th nucleotide and glutamic acid is replaced by valine in the resulting β globin chain (Ingram 1956; Bunn 1997; Rees et al. 2010). Individuals with a single mutant β chain are classified as having sickle cell trait; homozygotes are classified as having SCD.
Under conditions of low oxygen tension, Haemoglobin S (HbS) undergoes a sol–gel transformation and polymerises and distorts the red blood cell (RBC), causing it to be spiculated at the edges, a phenomenon known as sickling. Deformability of the erythrocytes is reduced, so is their ability to pass through the microcirculation. Sickling of numerous erythrocytes leads to vascular blockage and tissue ischaemia (White & Heagan 1970; Alexy et al. 2010). Depending on the tissue involved, this may manifest as a vaso-occlusive crisis of the bones, lungs, central nervous system or other tissues. Secondary sequelae include heightened susceptibility to bacterial infections due to repeated infarction and involution of the spleen (Johnston et al. 1975).
Sickle cell disease shows marked phenotypic variability, which has been largely ascribed to two major genetic factors – foetal haemoglobin concentrations and co-inheritance of α-thalassaemia (Steinberg 2005; Sebastiani et al. 2010; Thein 2011). While SCD and α-thalassaemia lead to anaemia via different mechanisms, paradoxically, co-inheritance of α-thalassaemia with SCD, which occurs in about 30% of patients with sickle cell anaemia, attenuates the phenotypic presentation of SCD itself. This happens because the abnormal haemoglobin gene created by the thalassaemia reduces the concentrations of HbS in each erythrocyte and in so doing inhibits HbS polymerisation (Steinberg 2005). This observation was in fact one of the key clues to devising strategies for treating individuals with SCD. For example, enhanced or persistent expression of foetal haemoglobin is now known to attenuate the severity of SCD – and explains why SCD does not manifest clinically in young infants (Stuart & Nagel 2004). Several therapeutic agents targeted at increasing the levels of foetal haemoglobin have been explored, the most widely used is the cytotoxic agent hydroxyurea (Trompeter & Roberts 2009). Hydroxyurea inhibits ribonucleotide reductase, the enzyme that catalyses the conversion of ribonucleotides to deoxyribonucleotides. This reduces the production of RBCs containing high HbS levels that arise from rapidly dividing progenitor cells, while favouring cells with high Haemoglobin F (HbF) levels (F cells) that arise from slow-dividing progenitor cells (Brun et al. 2003; Platt 2008). Clinically, hydroxyurea reduces haemolysis and the number of irreversibly sickled cells that are removed from circulation by the spleen. Additionally, hydroxyurea is metabolised to nitric oxide, which causes vessel dilation, reducing vascular blockage and improving tissue perfusion (Brun et al. 2003; Platt 2008). Hydroxyurea has been used successfully to reduce adverse events in SCD, and studies conducted in the United States suggest that it reduces morbidity and prolongs life (Dover & Charache 1989; Steinberg et al. 2003; Zimmerman et al. 2004).
The interaction between malaria and sickle cell disease
Malaria is the most common arthropod-borne infectious disease in the world. The WHO estimates there were 216 million malaria cases and 655 000 related deaths in 2010, 91% of which were in Africa. Most cases were due to P. falciparum and occurred in children under the age of five (World Health Organization 2011). Other mortality estimates for malaria in 2010 are as high as 1 238 000 with most deaths occurring in children under 5 in the WHO West African region (Murray et al. 2012). In contrast with Plasmodium vivax and Plasmodium ovale, P. falciparum is able to infect erythrocytes at multiple stages of development, a feature that may result in severe anaemia and other complications. Microocclusion of the vascular beds by infected erythrocytes causes ischaemia and direct tissue injury, manifesting as renal failure, cerebral malaria, pulmonary insufficiency and massive splenomegaly.
Malaria is a major environmental determinant of morbidity and mortality in SCD in most parts of Sub-Saharan Africa (Konotey-Ahulu 1971; Fleming 1989). It appears that malaria and the haemoglobin S gene are intimately connected being that they have similar geographic distributions (Serjeant 1989; Piel et al. 2010), and in the heterozygous state, the sickle cell gene confers substantial protection against clinical malaria (Ayi et al. 2004). Sickle cell trait is estimated to reduce malaria admission rates by 70% and is 90% protective against severe and complicated malaria (Williams et al. 2005). Similarly, sickle cell trait reduces severe malarial anaemia by 60% (Aidoo et al. 2002). Some of the suggested mechanisms by which the sickle cell gene protects against malaria include increased sickling and early senescence of phagocytosed erythrocytes, reduced parasite invasion and retarded development of P. falciparum in HbS erythrocytes at reduced oxygen tension, and the development of antibodies to the band 3 protein (Ayi et al. 2004; Kennedy 2010).
Somewhat paradoxically, the homozygous SCD state is associated with increased susceptibility to malaria (Uzoegwu & Onwurah 2003). Several laboratory and epidemiological studies have demonstrated that malaria plays a causal role in bacteraemia, particularly those due to Gram-negative enteric bacteria, including Escherichia coli and non-typhoidal salmonellae (Bronzan et al. 2007; Mackenzie et al. 2010; Were et al. 2011; Cunnington et al. 2012). This observation is hypothesised to result from sequestration of P. falciparum in the intestinal microvasculature, allowing for translocation of intestinal bacteria (Scott et al. 2011). Individuals with sickle cell trait have reduced incidence of bacteraemia in settings where malaria transmission is high, a benefit that is lost when leaving malaria zones. As with the risk of malaria, bacteraemia incidence was significantly higher among homozygotes (Scott et al. 2011).
The spleen plays an important role in the immunity that develops after repeated bouts of malaria episodes (Engwerda et al. 2005), and it is the central area of malaria parasite clearance. Parasite clearance is presumably prolonged in persons with impaired splenic function, and the hyposplenism that accompanies sickle cell anaemia may in part explain the reduced protection against malaria (Chotivanich et al. 2002; Engwerda et al. 2005; Buffet et al. 2011).
Several studies that compared individuals with surgical splenectomy to those with functioning spleens have demonstrated significantly more malaria parasitaemia in those with splenectomy (Boone & Watters 1995; Bach et al. 2005).
In the setting of SCD, malaria further reduces tissue perfusion by causing RBCs to adhere to the linings of small blood vessels with resulting vaso-occlusion and by promoting RBC destruction and decrease in tissue oxygen levels. The reduced oxygen tension from hypoperfusion further promotes sickling with consequent worsening of vaso-occlusion and increased erythrocyte destruction. As both malaria and SCD exacerbate each other, a vicious cycle of pathogenesis is established, as summarised in the model proposed in Figure 2. The organ most directly affected by these malignant synergisms is the spleen, which is adversely affected by both conditions. As a consequence of reduced splenic function, patients with SCD have reduced immunity and are prone to various infections including encapsulated pathogens and malaria, thus creating a cycle of splenic damage, increased susceptibility to infections and malaria, and repeated bouts of sickle cell crisis.
Several observational studies provide support for this pathophysiological model. In a case–control study conducted in Kenya from 2001 to 2004, the risk of complicated and uncomplicated malaria was the same in patients with sickle cell anaemia compared with non-SCD patients, but those with SCD who developed clinical malaria had a higher risk of severe anaemia and of mortality from malaria (McAuley et al. 2010). In Tanzania, Makani et al. (2010) documented that patients with SCD were less likely to develop malaria than controls (non-SCD patients); however, patients with SCD who were hospitalised and had malaria parasitaemia had a much higher risk of death during that hospitalisation than hospitalised controls with malaria parasitaemia (OR = 4.9 95% CI 1.04–23.20; P = 0.04).
Strategies for mitigating the malignant synergism between sickle cell disease and malaria
Clinical evidence available in target group (persons with sickle cell disease living in malaria-endemic regions)
Malaria chemoprophylaxis: In a bid to reduce the burden of malaria in patients with SCD, routine malaria chemoprophylaxis is recommended by physicians, ministries of health and by the World Health Organization for certain high-risk groups such as pregnancy and children under the age of 5 years (Konotey-Ahulu 1971; Onwubalili 1983; Kotila et al. 2007; WHO African Region 2010). However, the use of these drugs in accordance with local recommendations is unclear. Furthermore, several studies have suggested that persons with SCD may be protected from malaria in degrees similar to that established for those with HbAS bringing to question the relevance of antimalaria chemoprophylaxis (Komba et al. 2009; Makani et al. 2010). In addition, recent reports show widespread resistance to chloroquine and sulphadoxine–pyrimethamine (SP), two cost-effective drugs widely employed in malaria chemoprophylaxis for persons with SCD.
Based on the reasons above and the obvious gaps in knowledge concerning the role of chemoprophylaxis in SCD, we examined the role of malaria chemoprophylaxis in SCD, in the era of antimicrobial resistance and incongruous data on malaria in SCD.
We identified a total of six published randomised trials spanning a timeline of 45 years (1962–2008) all of which were conducted in eastern and western Sub-Saharan Africa (Table 3). The drugs involved were chloroquine, SP, proguanil, pyrimethamine and mefloquine.
|First author||Date and duration||Location||Sample size||Study design||Results||Limitations and generalisability|
|Lewthwaite C.J.||1962;Follow-up period aggregate of 1 year||Kampala, Uganda||24 children||Assigned to receive S/C CQ 5 mg/kg and ultra-long-acting BPG 1.2 MU I.M or 0.5 ml sterile water S/C|| |
In the CQ+BPG group there was 1 death; no crises recorded
4 crises episodes in 4 patients in control group, 1 death.Blood transfusion and hospital admission were required in all 4 patients with crises.
No significant difference in the mean Hb and WBC counts between groups
MP positive 12× in CQ+BPG group, 13× in control group
Methods of randomisation unknown.
Success at blinding uncertain as placebo was one (1) drug while treatment was with two (2).
Small sample size, loss to follow-up of at least 11 (45.8%).
No effect measures
Only preliminary results available
|Warley M.A.||August 1962–May 1965.||Kampala, Uganda|| |
75% were under 6 yearslargely of the same tribe
Prophylactic group given 1.2 MU long-acting BPG and 2 tablets of 200 mg CQ monthly with 7-day spacing
Placebo received 0.5 ml sterile water S/C
Malaria: 7 episodes in the treatment group, 21 episodes in the control group (no P-value reported)
Dactylitis: 1.8 attacks in treatment group, 5.2 attacks among control (P < 0.1).Mean Hb values: Significantly higher in the treatment group (P < 0.02)
Old study done with CQ.
Combined two interventions therefore measured effects difficult to attribute to either therapy alone.
Diagnostic criteria for malaria are not defined.
Study is at best single blinded
|Nwokolo C|| |
|Multicentre, Nigeria||113 participants above the age of 5 years||Treatment groups were randomly assigned to weekly mefloquine or daily proguanil|| |
Similar in malaria prevention efficacy, tolerability profile, and occurrence of adverse events. (P > 0.05)
Greater reduction in ALT levels in the mefloquine group at the end of the study (P-value not reported)
|Eke F.U||Published 2003 Follow-up for 9 months||Port-Harcourt, Nigeria||101 patients aged between 1 and 16 years 97 of 101 completed the study|| |
Randomly assigned into three groups
Given either 0.5 mg/kg/week of pyrimethamine, 1.5 mg/kg/day of proguanil or placebo (vit. c)
Patients were followed up at 2-week intervals for 3 months then monthly for the rest of the study
No significant difference in the prevalence of malaria parasite across the three groups
Significant reduction in the mean parasite density in the proguanil compared with the pyrimethamine group (P = 0.045)
Pyrimethamine group had significantly less parasite density than placebo.
(P < 0.05).
Sickle-related events: no significant difference.
Splenomegaly: more frequent in those on proguanil or placebo.
(P < 0.05)
Blood transfusions: more in patients on placebo compared with the other 2 groups. (P < 0.05)Hospitalisations: More in the placebo group compared with the other 2 groups, although notstatistically different across groups
Effect of malaria prophylaxis may be less pronounced in areas with less endemicity
|Nakibuuka V.||October 2006–February 2007. 5 months||Kampala, Uganda||242 children between the ages of 6 months and 12 years|| |
Children were randomised to receive either sulphadoxine–pyrimethamine (SP) (25/5 mg/kg) or CQ (5 mg/kg) monthly with
Weekly follow-up for a month15 children were lost to follow-up (7-SP, 8-CQ)
14% of children in SP arm developed malaria compared with 26% in the CQ arm (OR 1.98, 95 CI 1.023–3.82).
Higher proportion of malaria-related admissions in the CQ arm compared with the SP arm (5.7% vs. 2.5% OR 2.4 P = 0.223)
No statistically significant difference in the all-cause admissions between both groups
|Significantly more children on CQ were using bed nets as such observed results may be an underestimate|
|Diop S.|| |
September 2007 to February 2008
|Dakar, Senegal||60 participants with a mean age of 24 years||Randomly assigned to receive IPT with SP (25 mg/kg/1.25 mg/kg) or placebo monthly|| |
No statistically significant reduction in number of VOCs or hospitalisations
46% reduction in number of complaints (P = 0.002)
75% reduction in number of patients transfused (P = 0.001)
Short follow-up period
Small sample size.
Peak malaria transmission is from July to October but study included only two of these months
Of particular relevance were the four studies that assessed the overall efficacy of malaria prophylaxis in the setting of SCD compared with no prophylaxis. Unfortunately, all of these suffered in varying degrees from insufficient sample size and/or duration of follow-up. The earliest study we located, conducted prior to the emergence of widespread antimalarial resistance, assessed the effect of chloroquine prophylaxis on Ugandan children with SCD (Lewthwaite 1962). While the sample size was small, leaving the study seriously underpowered (24 subjects), there was a trend towards lower rates of death and sickle cell crises among those who received prophylaxis vs. the control group (RR 0.24, 95% CI 0.03–1.7). In a similar study assessing the combined effect of benzathine penicillin and chloroquine, Warley et al. (1965) found significantly reduced rates of malaria parasitaemia and anaemia, as well as reduced incidence of dactylitis, one of the more common manifestations of sickle cell crises: 1.8 episodes per intervention child vs. 5.2 attacks in the control children. More recently, Diop et al. (2011) in Senegal have demonstrated a reduction in the need for blood transfusion in patients with SCD on SP prophylaxis compared with those who received placebo; no differences were seen in rates of vaso-occlusive crises, although their ability to detect these endpoints may have been limited by the sample size of sixty subjects followed for at most 4 months. These results are similar to the findings of Eke and Anochie who, in 2003, demonstrated that daily proguanil or weekly pyrimethamine, when compared with placebo, was effective in reducing malaria parasite density and the need for blood transfusion in patients with SCD. Collectively, these studies indicate that malaria chemoprophylaxis offers some protection against malaria in SCD and reduction in blood transfusion needs. However, the effects of prophylaxis on sickle cell endpoints are less clear. While several studies suggested a trend towards lower rates, none appeared to have had sufficient statistical power to reach any solid conclusions.
Two additional studies compared the effectiveness of different regimens of malaria chemoprophylaxis in patients with SCD (Table 3). The first demonstrated that SP was better than chloroquine at reducing malaria events in patients with SCD (Nakibuuka et al. 2009) This may have been due to the high rates of resistance to chloroquine compared with SP in the malaria parasites within the regions the study was conducted. Eke and Anochie noted that in persons with SCD, daily proguanil was more effective at reducing malaria parasite density than weekly pyrimethamine, although there were no significant differences in clinical outcomes between the two drugs. The study by Nwokolo et al. demonstrated similar clinical effectiveness and tolerance between mefloquine and proguanil, although significant biochemical profile differences were recorded between the two drugs.
In summary, based on guidelines shown in Table 2, malaria chemoprophylaxis appears to offer reduction in the following
- Anaemia: II/A.
- Clinical Malaria: II/B.
- Malaria Parasite Levels/Parasite Density: II/B.
- Sickle-Related Events: II/C.
- Malaria-Related Hospitalisations: II/C.
No clinical evidence available in target group but laboratory evidence suggests benefit
Hydroxyurea, the only drug that has been demonstrated to have long-term beneficial effects in SCD such as reducing hospital admissions, protecting against sickling-related events, increasing the quality of life and improving longevity, has no documented studies on the clinical effects of the drug on malaria or in malarious regions. However, experimental models suggest that hydroxyurea, like other ribonucleotide reductase inhibitors, possesses antimalarial properties that may be significant at the doses it is given in SCD (Holland et al. 1998; Pino et al. 2006). One of the major concerns about hydroxyurea use in malaria endemic-zones stems from its ability to upregulate intercellular adhesion molecule 1 (ICAM-1) expression in endothelial cells. As ICAM-1 is a cell surface receptor for the adhesion of erythrocytes infected with P. falciparum, it is theoretically possible that this could lead to enhanced replication in erythrocytes (Brun et al. 2003; Pino et al. 2006). It is somewhat reassuring that in contrast to this hypothetical concern, hydroxyurea-treated mice had significantly reduced levels of malaria parasitaemia and reduced mortality from malaria (Pino et al. 2006).
Haemoglobin F reduces malaria parasite proliferation in the human erythrocyte at degrees similar to that for HbS (Pasvol et al. 1976 Pasvol et al. 1977; Wilson et al. 1977; Shear et al. 1998). As persons with SCD on hydroxyurea have elevated HbF levels, the drug may offer these individuals substantial protection from malaria.
Several other studies have demonstrated that hydroxyurea therapy in SCD is associated with preservation of splenic function and retardation/improvement of splenic dysfunction (Claster & Vichinsky 1996; Santos et al. 2002; Hankins et al. 2005, 2008). This improvement in splenic function by hydroxyurea may be useful in improving immunity against malaria in persons with SCD residing in malaria-endemic regions. Details of these studies can be found in Table 4.
|Mechanism||Author, date||Type of study||Summary of findings||Quality of evidence/Strength of recommendation|
|Haemoglobin F (HbF) protects against Malaria||Pasvol et al. (1976)||Laboratory Experiment, Human Samples (in vivo)|| |
Plasmodium falciparum distribution and growth was compared in erythrocytes containing either adult or foetal haemoglobin in vitro.
There was a significant retardation of parasite growth in vitro in cells containing HbF
|No clinical studies|
|Pasvol et al. (1977)||Laboratory Experiment, Human Samples (in vivo)|| |
Compared the rates of invasion and growth of P. falciparum in red blood cells in those containing HbA and those with HbF in an in vitro culture.
There was significant retardation of parasite growth in HbF cells compared with HbA cells
|Wilson et al. (1977)||Laboratory Experiment, Human Samples (in vivo)|| |
Comparing P. falciparum parasitisation in cord blood (high in HbF) to that in adult blood (high in HbA)
Rate of parasitisation was faster in cord blood than in adult blood
Parasite growth was significantly retarded in cord blood compared with the adult blood
|Shear et al. (1998)||Laboratory Experiment Transgenic mice (in vivo)|| |
Rates of parasitisation and growth of 2 strains of rodent malaria were compared. Transgenic (γ) mice expressing 40% to 60% α2 Mγ2 haemoglobin (foetal haemoglobin) and normal mice infected with rodent malaria.
When mice were infected with Plasmodium chabaudi adami, rates of parasitisation and parasite clearance were higher in the transgenic mice compared with their controls.
When mice were infected with Plasmodium yoelii 17XNL (lethal form of malaria), parasitisation rates were similar; parasite clearance was quicker and complete in transgenic mice (HbF) compared with control mice.
The faster rates of parasite clearance were also demonstrated in splenectomised transgenic mice compared with splenectomised control mice
|HU possesses intrinsic antimalaria properties||Holland et al. (1998)||Laboratory studies||Hydroxyurea along with other RNR inhibitors was tested in an in vitro culture system for potential antimalarial activities.Hydroxyurea inhibited the growth of malaria parasite, although high concentrations were needed to achieve 50% inhibition of parasite (IC50)||No clinical studies|
|Pino et al. (2006)||Laboratory studies|| |
The effects of hydroxyurea on rodent malaria in mice (Plasmodium berghei)
High dose HU (200 mg/kg/day) was administered to some mice. Others weren't treated with HU.
Parasitaemia was significantly lower in treated mice compared with the untreated mice
|HU improves splenic function||Claster and Vichinsky (1996)||Case series|| |
Report of 2 SS patients with reversal of splenic dysfunction after 30 months and 24 months.
In both patients peak HbF levels ranged from 25% to 30%
|Santos et al. (2002)||Prospective Cohort|| |
Twenty-one patients aged 3–22 years;
14 SS, 7 Sbeta (0) underwent splenic scintigraphy prior to HU initiation and after 6 and 12 months of treatment.
At baseline, 9 SS and 1 Sbeta (0) were functionally asplenic, 5 SS and 6 Sbeta (0) patients had impaired splenic function.
One year after treatment, splenic function improved in 10 patients, was unchanged in 8 patients and worsened in 3
|Hankins et al. (2005)||Prospective study/ clinical trial extension|| |
Twenty-one children originally involved in a pilot trial of hydroxyurea (HUSOFT) were offered continued therapy for a mean duration of about 5 years.
After 4 years of hydroxyurea herapy, only 6 (43%) patients were functionally asplenic (absent radionucleotide uptake) upon study completion, in contrast to the expected 94% incidence of asplenia among untreated age-matched children with SCA based on red cell pit counts in the CSSCD (P < 0.001).Two infants with markedly diminished splenic function regained normal splenic uptake after 4 years of HU therapy.
|Hankins et al. (2008)||Retrospective cohort|| |
Forty-three children who had radionuclide testing of the spleen before and during HU therapy were retrospectively assessed.
Median follow-up period at maximum tolerated dose was 2.6 years.
At baseline, 93% were asplenic or had markedly reduced splenic function. At follow-up, 14% (6) completely recovered splenic function, and 5% (2) had preserved splenic function.
The Hb concentration in these eight children on hydroxyurea therapy was significantly higher than those without improved splenic function (9.1 vs. 8.6 g/dl, P = 0.01)
Although we found no documented clinical studies on hydroxyurea in Sub-Saharan Africa, a prospective study of 47 Tunisian children with SCD followed up for average duration of 52 months showed significant reduction in hospitalisation, increase in haemoglobin levels and an overall improvement in the clinical picture of the patients (Mellouli & Bejaoui 2008). While this study suggests that hydroxyurea is beneficial in North African children, it was conducted in a country that is malaria-free, and therefore, the results cannot be extrapolated to children with SCD in Sub-Saharan Africa.
Hydroxyurea has been successfully used in very young children. A recent landmark clinical trial on the use of hydroxyurea in children as young as 9 months of age showed that hydroxyurea was both safe and efficacious in reducing clinical events such as pain and dactylitis, while increasing haemoglobin and foetal haemoglobin (Wang et al. 2011). Despite these, the fear of toxicity, inability to cope with adverse reactions, and the high cost of purchase and monitoring the use of this antineoplastic drug in most developing countries have hindered its use.
No clinical or laboratory evidence in target group but clinical evidence in other groups suggest benefit
Promising results from malaria vaccine trials have been recently published. The RTS,S/AS01E vaccine in children aged 6–10 weeks at first vaccination had a 1-year post-third-dose vaccine efficacy (VE) ranging from 61.6%, (95% CI 35.6–77.1; P = 0.0003) in children randomised to 0-, 1- and 2-month dosing schedule to 63.8% (40.4–78.0; P < 0.0001) in children randomised to 0-, 1- and 7-month dosing schedule in a phase 2 trial conducted in Mali and 45.8% (24.1, 64.3, P = 0.0004) over 15 months in a trial conducted on healthy Kenyan and Tanzanian children aged 5–17 months (Asante et al. 2011; Olotu et al. 2011). By contrast, the recent FMP2.1/AS02A trial did not show significant protection against clinical malaria, although it had a strain-specific VE of 64.3% (Thera et al. 2011). Despite these intriguing results, it will take several years for these vaccines to come in to commercial use, and their protective efficacy will need to be assessed in individuals with SCD.
The emphasis of malaria prevention programmes has shifted from only chemoprophylaxis to multiple strategies such as the use of long-lasting insecticide-treated nets (LLINs), intermittent preventive therapy in high-risk groups like pregnant women and young children and the use of environmental control, especially indoor residual spraying (World Health Organization 2011). Although these strategies have yielded some success generally, it is yet to be determined how effective they will be in primarily SCD populations with respect to SCD-related outcomes, cost-effectiveness and sustainability.
We found that malaria chemoprophylaxis provides some benefits in patients with SCD, although the extent of the benefits differs across trials. In particular, the efficacy studies unanimously showed that malaria prophylaxis reduced the need for blood transfusion, an indication that it reduces the risk of severe malarial anaemia. The effect of malaria chemoprophylaxis on sickle-related events was less evident, but much of this may reflect the limitations of the trials themselves (e.g. small sample sizes, short durations of follow-up, lack of blinding and inadequate allocation).
Nevertheless, decisions on malaria chemoprophylaxis in patients with SCD remain challenging for several reasons. Based on quality, only three of the trials, Warley et al., Eke and Anochie, and Nakibuuka et al., are of high-quality standards with regard to methodology and standards of reporting (Moher et al. 2001). The trials conducted were also in areas of high malaria endemicity and may be less applicable to other regions of Sub-Saharan Africa. More importantly, much of this literature is decades old, predating the emergence of high rates of drug resistance. Chloroquine resistance has been reported since the early 1960s (Young & Moore 1961) and is now widespread across all malaria-endemic areas (Guerin et al. 2002). Similarly, SP treatment failure rates range from about 19% to 53% in Africa (World Health Organization 2010). Although proguanil resistance has been reported, it is not as widely spread as chloroquine and SP resistance. However, it is more expensive and requires daily use and thus is more prone to problems with adherence. This creates a major barrier to devising a unified policy regarding prophylactic antimalarials in patients with SCD, as the alternative medications are either unsuitable for use in this role by reason of pharmacokinetics (artemesinin monotherapy) or toxicity and/or expense (mefloquine, amodiaquine, halofantrine and artemether–lumefantrine). Given the continually evolving nature of malaria drug resistance, developing consensus guidelines for chemoprophylaxis of SCD in the future may be difficult without new studies of safe and effective drugs with longer half-lives.
Consequently, there is, in our view, a pressing need to consider alternative approaches to reducing malaria-associated morbidity in patients with SCD. For example, hydroxyurea appears to provide clinical benefits both for SCD and malaria. Because there is little evidence of hydroxyurea therapy in malaria-prone SCD populations, its use would need to be defined by, and policy informed by, well-conducted studies designed to assess both sickle cell- and malaria-related outcomes, efficacy, long-term effectiveness and safety. Similarly, recent advances in malaria vaccines hold great promise for patients with SCD.